Skip to main content

Candel Therapeutics, Inc.

CADL
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001841387

In the last 90 days, Candel Therapeutics, Inc. insiders filed 0 open-market purchases and 2 sales; 137 institutions reported holding it in 13F filings for Q2 2026, worth $518.9M in total; no superinvestor holds it.

Q3 2025 vs. Q2 2025

How the institutions holding Candel Therapeutics, Inc. changed between Q2 2025 and Q3 2025.

All holders in Q3 2025All holders in Q2 2025

13F holders of CADL: Q2 2025 compared with Q3 2025
MeasureQ2 2025Q3 2025Change
Holders7881+3
Shares23.0M22.7M−369.0K (−1.6%)
Value$116.6M$115.6M−$948.7K (−0.8%)

New holders (15)

Institutions that held Candel Therapeutics, Inc. at the end of Q3 2025 but not at the end of Q2 2025.

Institutions new to CADL in Q3 2025
InstitutionSharesValue% of portfolio
Citadel Advisors LLC252,291$1.29M0.00%
Millennium Management LLC136,670$697.0K0.00%
Kovitz Investment Group Partners, LLC79,316$404.5K0.00%
Lido Advisors, LLC60,201$307.0K0.00%
HB Wealth Management, LLC58,345$297.6K0.00%
State of Wisconsin Investment Board54,047$275.6K0.00%
Balyasny Asset Management LLC49,483$252.4K0.00%
Quadrature Capital Ltd13,831$70.5K0.00%
Quarry LP4,200$21.4K0.01%
Russell Investments Group, Ltd.3,258$16.6K0.00%
Optiver Holding B.V.656$3.35K0.00%
EverSource Wealth Advisors, LLC86$4390.00%
The PNC Financial Services Group, Inc.64$3260.00%
SRS Capital Advisors, Inc.54$2750.00%
Sunbelt Securities, Inc.27$1380.00%

Sold out (12)

Institutions that held Candel Therapeutics, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.